Live Breaking News & Updates on Oric Pharmaceuticals Inc|Page 6

Stay updated with breaking news from Oric pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Insider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Insider Sells $45,372.38 in Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) insider Pratik S. Multani sold 5,282 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $8.59, for a total value of $45,372.38. Following the completion of the sale, the insider now directly owns 23,809 shares […] ....

United States , Pratiks Multani , Pharmaceuticals Daily , Pharmaceuticals Inc , Ameritas Investment Partners Inc , Pharmaceuticals Stock , Acadian Asset Management , Royal Bank , Group One Trading , Securities Exchange Commission , Oric Pharmaceuticals Inc , Pharmaceuticals Company Profile , Get Free Report , Exchange Commission , Investment Partners , Asset Management , Oric Pharmaceuticals , Nasdaq Oric , Insider Trading , Nsider Trades ,

ORIC Pharmaceuticals Inc. (ORIC) Announces 12.14M Share Offering by Selling Stockholders

ORIC Pharmaceuticals Inc. (ORIC) Announces 12.14M Share Offering by Selling Stockholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Oric Pharmaceuticals Inc ,

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Buy" by Analysts

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has earned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in […] ....

United States , Robertw Baird , Tower Research Capital , Alkeon Capital Management , Oric Pharmaceuticals Inc , Capital Management , Pharmaceuticals Daily , Algert Global , Sherbrooke Park Advisers , Pharmaceuticals Stock , Pharmaceuticals Inc , Pharmaceuticals Company Profile , Get Free Report , Park Advisers , Research Capital , Get Free , Oric Pharmaceuticals , Nasdaq Oric ,

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

ORIC Pharmaceuticals, Inc. announced initial data from the ongoing ORIC-114 Phase 1 dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer at the European. ....

United States , San Diego , South San Francisco , Oric Pharmaceuticals Inc , European Society Of Medical Oncology , European Society , Medical Oncology ,

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from Brokerages

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has earned an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in […] ....

United States , Robertw Baird , Pharmaceuticals Inc , Group One Trading , Oric Pharmaceuticals Inc , Acadian Asset Management , Pharmaceuticals Daily , Pharmaceuticals Stock Performance , Royal Bank , Ameritas Investment Partners Inc , Get Free Report , Investment Partners , Asset Management , Get Free , Oric Pharmaceuticals , Nasdaq Oric ,